Nomogram for the Prediction of Biochemical Incomplete Response in Papillary Thyroid Cancer Patients

References

• Lu Y, Jiang L, Chen C, Chen H, Yao Q. Clinicopathologic characteristics and outcomes of papillary thyroid carcinoma in younger patients. Medicine. 2020;9915:e19795. doi:10.1097/MD.0000000000019795
   Web of Science ®Google Scholar
• Lang BH, Shek TW, Wan KY. Impact of microscopic extra-nodal extension (ENE) on locoregional recurrence following curative surgery for papillary thyroid carcinoma. J Surg Oncol. 2016;113(5):526–531. doi:10.1002/jso.2418026792294
   PubMed Web of Science ®Google Scholar
• Aldawish M, Jha N, McEwan AJ, Severin D, Ghosh S, Morrish DW. Low but measurable stimulated serum thyroglobulin levels <2 µg/L frequently predict incomplete response in differentiated thyroid cancer patients. Endocr Res. 2014;39(4):157–163.24460082
   PubMed Web of Science ®Google Scholar
• Deng Y, Zhu G, Ouyang W, et al. Size of the largest metastatic focus to the lymph node is associated with incomplete response of PN1 papillary thyroid carcinoma. Endocr Pract. 2019;25(9):887–898. doi:10.4158/EP-2018-058331170371
   PubMed Web of Science ®Google Scholar
• Shen FC, Hsieh CJ, Huang IC, Chang YH, Wang PW. Dynamic risk estimates of outcome in Chinese patients with well-differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation. Thyroid. 2017;27(4):531–536. doi:10.1089/thy.2016.047928007013
   PubMed Web of Science ®Google Scholar
• Qu Y, Huang R, Li L. Low- and high-dose radioiodine therapy for low-/intermediate-risk differentiated thyroid cancer: a preliminary clinical trial. Ann Nucl Med. 2017;31(1):71–83. doi:10.1007/s12149-016-1133-427757803
   PubMed Web of Science ®Google Scholar
• Danilovic DLS, Castroneves LA, Suemoto CK, et al. Is there a difference between minimal and gross extension into the strap muscles for the risk of recurrence in papillary thyroid carcinomas. Thyroid. 2020;30(7):1008–1016. doi:10.1089/thy.2019.075332059626
   PubMed Web of Science ®Google Scholar
• Yoon J, Yoon JH, Han K, et al. Ultrasonography surveillance in papillary thyroid carcinoma patients after total thyroidectomy according to dynamic risk stratification. Endocrine. 2020;69(2):347–357. doi:10.1007/s12020-020-02347-932449109
   PubMed Web of Science ®Google Scholar
• Randolph GE, Duh QY, Heller KS, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. 2012;22(11):1144–1152. doi:10.1089/thy.2012.004323083442
   PubMed Web of Science ®Google Scholar
• Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.26462967
   PubMed Web of Science ®Google Scholar
• Tuttle RM. Optimal management of a biochemical incomplete response to therapy in differentiated thyroid cancer: aggressive treatment or cautious observation. Endocrine. 2014;46(3):363–364. doi:10.1007/s12020-014-0213-224615658
   PubMed Web of Science ®Google Scholar
• Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20(12):1341–1349.21034228
   PubMed Web of Science ®Google Scholar
• Vaisman F, Momesso D, Bulzico DA, et al. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin Endocrinol. 2012;77(1):132–138. doi:10.1111/j.1365-2265.2012.04342.x
   PubMed Web of Science ®Google Scholar
• Momesso DP, Tuttle RM. Update on differentiated thyroid cancer staging. Endocrinol Metab Clin North Am. 2014;43:401–421. doi:10.1016/j.ecl.2014.02.01024891169
   PubMed Web of Science ®Google Scholar
• Momesso DP, Vaisman F, Yang SP, et al. Dynamic risk stratification in patients with differentiated thyroid cancer treated without radioactive iodine. J Clin Endocrinol Metab. 2016;101(7):2692–2700. doi:10.1210/jc.2015-429027023446
   PubMed Web of Science ®Google Scholar
• Vaisman F, Tala H, Grewal R, Tuttle RM. In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. Thyroid. 2011;21(12):1317–1322. doi:10.1089/thy.2011.023222136267
   PubMed Web of Science ®Google Scholar
• Calò PG, Medas F, Conzo G, et al. Intraoperative neuromonitoring in thyroid surgery: is the two staged thyroidectomy justified? Int J Surg. 2017;41(Suppl 1):213–S20. doi:10.1016/j.ijsu.2017.02.001
   Web of Science ®Google Scholar
• Conzo G, Docimo G, Mauriello C, et al. The current status of lymph node dissection in the treatment of papillary thyroid cancer. A literature review. Clin Ter. 2013;164(4):2242–2246.
   Web of Science ®Google Scholar
• Docimo G, Tolone S, Ruggiero R, et al. Total thyroidectomy without prophylactic central neck dissection combined with routine oral calcium and vitamin D supplements: is it a good option to achieve a low recurrence rate avoiding hypocalcemia? A retrospective study. Minerva Chir. 2013;68(3):321–328.23774098
   PubMed Web of Science ®Google Scholar
• Mendoza ES, Lopez AA, Valdez VA, et al. Predictors of incomplete response to therapy among filipino patients with papillary thyroid cancer in a tertiary hospital. J Endocrinol Invest. 2016;39(1):55–62. doi:10.1007/s40618-015-0319-226036600
   PubMed Web of Science ®Google Scholar
• Zern NK, Clifton-Bligh R, Gill AJ, et al. Disease progression in papillary thyroid cancer with biochemical incomplete response to initial therapy. Ann Surg Oncol. 2017;24(9):2611–2616. doi:10.1245/s10434-017-5911-628585075
   PubMed Web of Science ®Google Scholar
• Xing M, Liu R, Liu X, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol. 2014;32(25):2718–2726. doi:10.1200/JCO.2014.55.509425024077
   PubMed Web of Science ®Google Scholar
• Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90(12):6373–6379. doi:10.1210/jc.2005-098716174717
   PubMed Web of Science ®Google Scholar
• Kowalska A, Walczyk A, Kowalik A, et al. Response to therapy of papillary thyroid cancer of known BRAF status. Clin Endocrinol. 2017;87(6):815–824. doi:10.1111/cen.13423
   PubMed Web of Science ®Google Scholar
• Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1998;83(4):1121–1127.9543128
   PubMed Web of Science ®Google Scholar
• Chung JK, Park YJ, Kim TY, et al. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin Endocrinol. 2002;57(2):215–221. doi:10.1046/j.1365-2265.2002.01592.x
   PubMed Web of Science ®Google Scholar
• Görges R, Maniecki M, Jentzen W, et al. Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur J Endocrinol. 2005;153(1):49–55. doi:10.1530/eje.1.0194015994745
   PubMed Web of Science ®Google Scholar
• Seo JH, Lee SW, Ahn BC, Lee J. Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18) F-FDGPET/CT. Clin Endocrinol. 2010;72(4):558–563. doi:10.1111/j.1365-2265.2009.03693.x
   PubMed Web of Science ®Google Scholar
• Adil A, Jafri RA, Waqar A, et al. Frequency and clinical importance of anti-Tg auto-antibodies (ATG). J Coll Physicians Surg Pak. 2003;13(9):504–506.12971869
   PubMedGoogle Scholar